Gene therapy specialist, Targeted Genetics (Seattle, WA) is to buy another gene therapy company, Genovo (Philadelphia, PA) in a stock swap valued at nearly $90 million. The acquisition brings Targeted a new partner, Biogen (Cambridge, MA), which has paid Genovo nearly $40 million since 1995 for marketing rights to liver- and lung-related genetic therapies. That deal has been extended and is now reportedly worth a potential $125 million to the Seattle company.